Literature DB >> 24958945

Simeprevir capsules.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2014 monograph topics are dapagliflozin, tasimelteon, treprostinil diolamine, avarofloxacin, and idelalisib. The DUE/MUE is on dapagliflozin.

Entities:  

Year:  2014        PMID： 24958945      PMCID： PMC4062751          DOI： 10.1310/hpj4904-376

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  8 in total

1.  Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

Authors:  Oliver Lenz; Leen Vijgen; Jan Martin Berke; Maxwell D Cummings; Bart Fevery; Monika Peeters; Goedele De Smedt; Christophe Moreno; Gaston Picchio
Journal:  J Hepatol       Date:  2012-11-07       Impact factor: 25.083

2.  Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

Authors:  Michael W Fried; Maria Buti; Gregory J Dore; Robert Flisiak; Peter Ferenci; Ira Jacobson; Patrick Marcellin; Michael Manns; Igor Nikitin; Fred Poordad; Morris Sherman; Stefan Zeuzem; Jane Scott; Leen Gilles; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Maria Beumont-Mauviel
Journal:  Hepatology       Date:  2013-10-11       Impact factor: 17.425

3.  Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.

Authors:  Michael Manns; Henk Reesink; Thomas Berg; Geoffrey Dusheiko; Robert Flisiak; Patrick Marcellin; Christophe Moreno; Oliver Lenz; Paul Meyvisch; Monika Peeters; Vanitha Sekar; Kenneth Simmen; Rene Verloes
Journal:  Antivir Ther       Date:  2011

4.  Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study.

Authors:  Christophe Moreno; Thomas Berg; Tawesak Tanwandee; Satawat Thongsawat; Hans Van Vlierberghe; Stefan Zeuzem; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt
Journal:  J Hepatol       Date:  2012-02-10       Impact factor: 25.083

5.  Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

Authors:  Henk W Reesink; Gregory C Fanning; Khalid Abou Farha; Christine Weegink; André Van Vliet; Gerben Van 't Klooster; Oliver Lenz; Fatima Aharchi; Kris Mariën; Pieter Van Remoortere; Herman de Kock; Fabrice Broeckaert; Paul Meyvisch; Els Van Beirendonck; Kenneth Simmen; René Verloes
Journal:  Gastroenterology       Date:  2009-10-21       Impact factor: 22.682

6.  Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Authors:  Stefan Zeuzem; Thomas Berg; Edward Gane; Peter Ferenci; Graham R Foster; Michael W Fried; Christophe Hezode; Gideon M Hirschfield; Ira Jacobson; Igor Nikitin; Paul J Pockros; Fred Poordad; Jane Scott; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Gastroenterology       Date:  2013-11-01       Impact factor: 22.682

7.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

8.  Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.

Authors:  Norio Hayashi; Chiharu Seto; Mai Kato; Yuji Komada; Shoichiro Goto
Journal:  J Gastroenterol       Date:  2013-09-05       Impact factor: 7.527
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.